K Bieroń

475 total citations
28 papers, 364 citations indexed

About

K Bieroń is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Molecular Biology. According to data from OpenAlex, K Bieroń has authored 28 papers receiving a total of 364 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cardiology and Cardiovascular Medicine, 8 papers in Surgery and 5 papers in Molecular Biology. Recurrent topics in K Bieroń's work include Antiplatelet Therapy and Cardiovascular Diseases (10 papers), Peripheral Artery Disease Management (5 papers) and Inflammatory mediators and NSAID effects (5 papers). K Bieroń is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (10 papers), Peripheral Artery Disease Management (5 papers) and Inflammatory mediators and NSAID effects (5 papers). K Bieroń collaborates with scholars based in Poland. K Bieroń's co-authors include Ryszard J. Gryglewski, E Kostka-Trąbka, A. Dembińska-Kieć, Ryszard Korbut, L Grodzińska, A Zmuda, Andrzej Szczeklik, Sebastian Nowak, Barbara Błaszczyk and Gryglewski Rj and has published in prestigious journals such as Nature, Stroke and European Journal of Pharmacology.

In The Last Decade

K Bieroń

27 papers receiving 328 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K Bieroń Poland 10 112 92 65 62 56 28 364
E Kostka-Trąbka Poland 10 85 0.8× 68 0.7× 54 0.8× 66 1.1× 53 0.9× 33 322
C McRae Australia 8 135 1.2× 115 1.3× 40 0.6× 39 0.6× 74 1.3× 14 446
P. C. Weber Germany 12 123 1.1× 64 0.7× 55 0.8× 63 1.0× 43 0.8× 26 433
Pierre Bessin France 6 52 0.5× 66 0.7× 32 0.5× 136 2.2× 41 0.7× 7 367
F. Tessari Italy 13 94 0.8× 38 0.4× 84 1.3× 49 0.8× 134 2.4× 25 462
Syed R. Baber United States 13 104 0.9× 61 0.7× 114 1.8× 100 1.6× 178 3.2× 22 450
Salvatore Rosanio United States 11 225 2.0× 52 0.6× 146 2.2× 60 1.0× 90 1.6× 17 472
C.M. Ingerman-Wojenski United States 9 202 1.8× 135 1.5× 105 1.6× 113 1.8× 81 1.4× 12 578
Sheldon Y. Freeberg United States 6 107 1.0× 58 0.6× 95 1.5× 52 0.8× 25 0.4× 7 363
Heather Harrison United Kingdom 9 88 0.8× 129 1.4× 45 0.7× 163 2.6× 23 0.4× 12 471

Countries citing papers authored by K Bieroń

Since Specialization
Citations

This map shows the geographic impact of K Bieroń's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K Bieroń with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K Bieroń more than expected).

Fields of papers citing papers by K Bieroń

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K Bieroń. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K Bieroń. The network helps show where K Bieroń may publish in the future.

Co-authorship network of co-authors of K Bieroń

This figure shows the co-authorship network connecting the top 25 collaborators of K Bieroń. A scholar is included among the top collaborators of K Bieroń based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K Bieroń. K Bieroń is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bieroń, K, et al.. (2005). Bencyclane - a new aspect of the mechanism of action in patients with peripheral arterial occlusive disease. Open-label, prospective, randomized trial. Jagiellonian University Repository (Jagiellonian University). 11(3). 157–172. 4 indexed citations
2.
Grodzińska, L, et al.. (2005). Simvastatin Effects in Normo‐ and Hypercholesterolaemic Patients with Peripheral Arterial Occlusive Disease: A Pilot Study. Basic & Clinical Pharmacology & Toxicology. 96(6). 413–419. 8 indexed citations
3.
Bieroń, K, et al.. (2002). Misoprostol as agonist of IP2 receptor.. PubMed. 53(4 Pt 1). 635–41. 1 indexed citations
4.
Grodzińska, L, et al.. (1998). Treatment of peripheral vascular disease with misoprostol(Cytotec(R)): A pilot study. Methods and Findings in Experimental and Clinical Pharmacology. 20(5). 439–439. 4 indexed citations
5.
Bieroń, K, et al.. (1998). Thrombolytic and antiplatelet action of xanthinol nicotinate (Sadamin): possible mechanisms.. PubMed. 49(2). 241–9. 5 indexed citations
6.
Gryglewski, Ryszard J., et al.. (1996). Thrombolytic action of ticlopidine: possible mechanisms. European Journal of Pharmacology. 308(1). 61–67. 35 indexed citations
7.
Grodzińska, L, et al.. (1996). Misoprostol (cytotec) in the treatment of peripheral ischaemic disease.. PubMed. 84(4). 415–6. 3 indexed citations
8.
Surdacki, Andrzej, et al.. (1994). Lack of beneficial effects of L-arginine infusion in primary pulmonary hypertension.. PubMed. 106(16). 521–6. 21 indexed citations
9.
Surdacki, Andrzej, et al.. (1994). LACK OF BENEFICIAL EFFECTS OF L-ARGININE PRIMARY PULMONARY HYPERTENSION. 106. 521–526.
10.
Mirkiewicz-Sieradzka, B, et al.. (1992). [Evaluation of the effectiveness of prostacyclin in the treatment of thrombosis of the central retinal vein using a double-blind method].. PubMed. 94(1). 13–5. 2 indexed citations
11.
Kuźniewski, Marek, et al.. (1990). Effect of Heparin and Prostacyclin/Heparin Infusion on Platelet Aggregation in Hemodialyzed Patients. ˜The œNephron journals/Nephron journals. 56(2). 174–178. 4 indexed citations
12.
Kostka-Trąbka, E, et al.. (1990). [Administration of prostacyclin in sudden deafness. Evaluation with the double blind method].. PubMed. 44(1). 62–5. 3 indexed citations
13.
Rj, Gryglewski, et al.. (1989). [Use of prostacyclin in patients with ischemic stroke. A double-blind method II].. PubMed. 22(4). 299–304. 4 indexed citations
14.
Dembińska-Kieć, A., et al.. (1985). Plasma antioxidant potency and serum copper levels in atherosclerosis.. PubMed. 37(2). 123–32. 3 indexed citations
15.
Kostka-Trąbka, E, et al.. (1985). Double-blind controlled trial of the therapeutic effects of prostacyclin in patients with completed ischaemic stroke.. Stroke. 16(5). 810–814. 27 indexed citations
16.
Gryglewski, Ryszard J., Sebastian Nowak, E Kostka-Trąbka, et al.. (1983). Treatment of ischaemic stroke with prostacyclin.. Stroke. 14(2). 197–202. 65 indexed citations
17.
Dembińska-Kieć, A., Ryszard Korbut, K Bieroń, E Kostka-Trąbka, & R.J. Gryglewski. (1983). Beta-pyridylcarbinol (RonicolR) releases a prostacyclin-like substance into arterial blood of patients with arteriosclerosis obliterans. Pharmacological Research Communications. 15(4). 377–385. 7 indexed citations
18.
Dembińska-Kieć, A., et al.. (1981). Prostacyclin and blood glucose levels in humans and rabbits. Prostaglandins. 21(1). 113–121. 16 indexed citations
19.
Dembińska-Kieć, A., et al.. (1981). Increased platelet activity after termination of prostacyclin infusion into man. Prostaglandins. 21(5). 827–832. 12 indexed citations
20.
Gryglewski, Ryszard J., et al.. (1977). Selective inhibition of thromboxane A2 biosynthesis in blood platelets. Nature. 267(5612). 627–628. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026